BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330,829 | -22.1% | 8,766 | -5.9% | 0.03% | -47.5% |
| Q2 2023 | $424,437 | +5.2% | 9,316 | -6.3% | 0.06% | +3.4% |
| Q1 2023 | $403,410 | -18.9% | 9,946 | +1.9% | 0.06% | -18.1% |
| Q4 2022 | $497,263 | -5.5% | 9,756 | -0.1% | 0.07% | -16.3% |
| Q3 2022 | $526,000 | -16.2% | 9,768 | 0.0% | 0.09% | -10.4% |
| Q2 2022 | $628,000 | -17.2% | 9,768 | -0.1% | 0.10% | -5.0% |
| Q1 2022 | $758,000 | -9.7% | 9,775 | 0.0% | 0.10% | -6.5% |
| Q4 2021 | $839,000 | +5.5% | 9,775 | -1.0% | 0.11% | -1.8% |
| Q3 2021 | $795,000 | -1.6% | 9,875 | -1.5% | 0.11% | -0.9% |
| Q2 2021 | $808,000 | -6.2% | 10,030 | -1.7% | 0.11% | -10.5% |
| Q1 2021 | $861,000 | -4.2% | 10,205 | -9.0% | 0.12% | -9.5% |
| Q4 2020 | $899,000 | -1.5% | 11,212 | -1.2% | 0.14% | -9.9% |
| Q3 2020 | $913,000 | -6.7% | 11,352 | -0.2% | 0.15% | -13.1% |
| Q2 2020 | $979,000 | -0.1% | 11,372 | -5.8% | 0.18% | -12.5% |
| Q1 2020 | $980,000 | -3.7% | 12,069 | -0.9% | 0.20% | +25.0% |
| Q4 2019 | $1,018,000 | -5.0% | 12,177 | -0.6% | 0.16% | -14.9% |
| Q3 2019 | $1,072,000 | +5.1% | 12,248 | -1.6% | 0.19% | +2.7% |
| Q2 2019 | $1,020,000 | -0.1% | 12,453 | -0.8% | 0.18% | -1.6% |
| Q1 2019 | $1,021,000 | +18.9% | 12,559 | -3.7% | 0.19% | +33.8% |
| Q4 2018 | $859,000 | -16.6% | 13,047 | -2.3% | 0.14% | -16.8% |
| Q3 2018 | $1,030,000 | +4.4% | 13,352 | -0.1% | 0.17% | -5.6% |
| Q2 2018 | $987,000 | +8.0% | 13,364 | -4.9% | 0.18% | +18.0% |
| Q1 2018 | $914,000 | +0.6% | 14,058 | -0.1% | 0.15% | +4.9% |
| Q4 2017 | $909,000 | +2.8% | 14,066 | -0.1% | 0.14% | +1.4% |
| Q3 2017 | $884,000 | +3.0% | 14,083 | -0.7% | 0.14% | +0.7% |
| Q2 2017 | $858,000 | +10.4% | 14,183 | -5.3% | 0.14% | +8.5% |
| Q1 2017 | $777,000 | +18.3% | 14,983 | +1.2% | 0.13% | +14.2% |
| Q4 2016 | $657,000 | -6.8% | 14,808 | 0.0% | 0.11% | -8.1% |
| Q3 2016 | $705,000 | +4.4% | 14,808 | -0.8% | 0.12% | +4.2% |
| Q2 2016 | $675,000 | +7.1% | 14,933 | -2.6% | 0.12% | +6.3% |
| Q1 2016 | $630,000 | +11.9% | 15,333 | +3.8% | 0.11% | +9.9% |
| Q4 2015 | $563,000 | +13.3% | 14,773 | -2.3% | 0.10% | +8.6% |
| Q3 2015 | $497,000 | -52.8% | 15,116 | +0.3% | 0.09% | -45.9% |
| Q2 2015 | $1,053,000 | +3.9% | 15,066 | +1.8% | 0.17% | +6.2% |
| Q1 2015 | $1,013,000 | -6.6% | 14,793 | 0.0% | 0.16% | -4.7% |
| Q4 2014 | $1,085,000 | +49.0% | 14,793 | +46.0% | 0.17% | +45.3% |
| Q3 2014 | $728,000 | +11.7% | 10,133 | +12.4% | 0.12% | +18.2% |
| Q2 2014 | $652,000 | +10.7% | 9,013 | +12.6% | 0.10% | +15.1% |
| Q1 2014 | $589,000 | +13.7% | 8,003 | +7.5% | 0.09% | +16.2% |
| Q4 2013 | $518,000 | +4.6% | 7,445 | -1.3% | 0.07% | 0.0% |
| Q3 2013 | $495,000 | -4.4% | 7,545 | +0.9% | 0.07% | -5.1% |
| Q2 2013 | $518,000 | – | 7,475 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |